Forest Labs' antibiotic ceftaroline gets unanimous support of FDA advisory panel
This article was originally published in Scrip
Executive Summary
Forest Labs got unanimous support from the US FDA anti-infective drugs advisory committee for its injectable antibiotic ceftaroline fosamil, with panellists agreeing that it should be approved for two indications: community acquired bacterial pneumonia and (CABP) and complicated skin and skin structure infections (cSSSI).